Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Aegerion Pharmaceuticals, Inc. Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 3.04||$ 25.06|
|Low||$ 2.80||$ 2.91|
The current last sale of $2.85 is -2.06% Lower thanthe 52 week low.
ETFs with AEGR as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0%||BioShares Biotechnology Products Fund (BBP)||-3.54 (-11.66%)|
Company Description (as filed with the SEC)
We are a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Our first product, lomitapide, received marketing approval, under the brand name JUXTAPID® (lomitapide) capsules ("JUXTAPID"), from the U.S. Food and Drug Administration ("FDA") in December 2012, as an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). We launched JUXTAPID in the U.S. in January 2013. ... More ...
Where does AEGR fit in the risk graph?
Nasdaq Official Price
|Annual EPS Est:||$-1.06|
|Quarterly EPS Est:||-0.54|